BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 27766406)

  • 1. CD164 identifies CD4
    Benoit BM; Jariwala N; O'Connor G; Oetjen LK; Whelan TM; Werth A; Troxel AB; Sicard H; Zhu L; Miller C; Takeshita J; McVicar DW; Kim BS; Rook AH; Wysocka M
    Arch Dermatol Res; 2017 Jan; 309(1):11-19. PubMed ID: 27766406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD164 and FCRL3 are highly expressed on CD4+CD26- T cells in Sézary syndrome patients.
    Wysocka M; Kossenkov AV; Benoit BM; Troxel AB; Singer E; Schaffer A; Kim B; Dentchev T; Nagata S; Ise T; Showe LC; Rook AH
    J Invest Dermatol; 2014 Jan; 134(1):229-236. PubMed ID: 23792457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TOX expression in different subtypes of cutaneous lymphoma.
    Morimura S; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
    Arch Dermatol Res; 2014 Nov; 306(9):843-9. PubMed ID: 25216799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of CD164 on Malignant T cells in Sézary Syndrome.
    Guenova E; Ignatova D; Chang YT; Contassot E; Mehra T; Saulite I; Navarini AA; Mitev V; Dummer R; Kazakov DV; French LE; Hoetzenecker W; Cozzio A
    Acta Derm Venereol; 2016 May; 96(4):464-7. PubMed ID: 26524186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revisiting the initial diagnosis and blood staging of mycosis fungoides and Sézary syndrome with the KIR3DL2 marker.
    Roelens M; de Masson A; Ram-Wolff C; Maki G; Cayuela JM; Marie-Cardine A; Bensussan A; Toubert A; Bagot M; Moins-Teisserenc H
    Br J Dermatol; 2020 Jun; 182(6):1415-1422. PubMed ID: 31487384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts.
    Lee CS; Ungewickell A; Bhaduri A; Qu K; Webster DE; Armstrong R; Weng WK; Aros CJ; Mah A; Chen RO; Lin M; Sundram U; Chang HY; Kretz M; Kim YH; Khavari PA
    Blood; 2012 Oct; 120(16):3288-97. PubMed ID: 22936659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence of an oncogenic role of aberrant TOX activation in cutaneous T-cell lymphoma.
    Huang Y; Su MW; Jiang X; Zhou Y
    Blood; 2015 Feb; 125(9):1435-43. PubMed ID: 25548321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relevance of the CD4+ CD26- subset in the identification of circulating Sézary cells.
    Bernengo MG; Novelli M; Quaglino P; Lisa F; De Matteis A; Savoia P; Cappello N; Fierro MT
    Br J Dermatol; 2001 Jan; 144(1):125-35. PubMed ID: 11167693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome.
    Zaki MH; Shane RB; Geng Y; Showe LC; Everetts SE; Presky DH; Wysocka M; Moore JS; Rook AH
    J Invest Dermatol; 2001 Jul; 117(1):119-27. PubMed ID: 11442758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EPHA4 is overexpressed but not functionally active in Sézary syndrome.
    Hameetman L; van der Fits L; Zoutman WH; Out-Luiting JJ; Siegal G; de Esch IJ; Vermeer MH; Tensen CP
    Oncotarget; 2015 Oct; 6(31):31868-76. PubMed ID: 26376612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of cell surface molecules characterizing human cutaneous T-cell lymphomas.
    Nikolova M; Bagot M; Boumsell L; Bensussan A
    Leuk Lymphoma; 2002 Apr; 43(4):741-6. PubMed ID: 12153159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
    Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
    Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
    Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
    Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TOX expression in cutaneous T-cell lymphomas: an adjunctive diagnostic marker that is not tumour specific and not restricted to the CD4(+)  CD8(-) phenotype.
    Schrader AM; Jansen PM; Willemze R
    Br J Dermatol; 2016 Aug; 175(2):382-6. PubMed ID: 26931394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.
    Xu J; Huang H; Wang S; Chen Y; Yin X; Zhang X; Zhang Y
    Arch Dermatol Res; 2020 Sep; 312(7):513-525. PubMed ID: 31676945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-181 contributes to downregulation of SAMHD1 expression in CD4+ T-cells derived from Sèzary syndrome patients.
    Kohnken R; Kodigepalli KM; Mishra A; Porcu P; Wu L
    Leuk Res; 2017 Jan; 52():58-66. PubMed ID: 27889686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sézary syndrome.
    Narducci MG; Arcelli D; Picchio MC; Lazzeri C; Pagani E; Sampogna F; Scala E; Fadda P; Cristofoletti C; Facchiano A; Frontani M; Monopoli A; Ferracin M; Negrini M; Lombardo GA; Caprini E; Russo G
    Cell Death Dis; 2011 Apr; 2(4):e151. PubMed ID: 21525938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential.
    Ballabio E; Mitchell T; van Kester MS; Taylor S; Dunlop HM; Chi J; Tosi I; Vermeer MH; Tramonti D; Saunders NJ; Boultwood J; Wainscoat JS; Pezzella F; Whittaker SJ; Tensen CP; Hatton CS; Lawrie CH
    Blood; 2010 Aug; 116(7):1105-13. PubMed ID: 20448109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Killer cell immunoglobulin-like receptor expression delineates in situ Sézary syndrome lymphocytes.
    Wechsler J; Bagot M; Nikolova M; Parolini S; Martin-Garcia N; Boumsell L; Moretta A; Bensussan A
    J Pathol; 2003 Jan; 199(1):77-83. PubMed ID: 12474229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression of cell adhesion molecule 1 and its splicing variants in Sézary cells and cell lines from cutaneous T-cell lymphoma.
    Yamaguchi M; Morizane S; Hamada T; Miyake T; Sugaya M; Iwata H; Fujii K; Haramoto-Shiratsuki R; Nakagawa Y; Miura M; Ohshima K; Morishita K; Takahashi T; Imada M; Okada K; Uehara J; Sowa-Osako J; Iwatsuki K
    J Dermatol; 2019 Nov; 46(11):967-977. PubMed ID: 31515833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.